Carrick licenses targeted ovarian cancer drug from BTG
Dublin, Ireland-based biopharma Carrick Therapeutics has licensed exclusive globl rights to develop and commercialise BTG’s targeted ovarian cancer drug BTG945.
Read More
Tag: BTG
BTG buys Irish med device group Novate
Specialist healthcare group BTG has snapped up med tech group Novate Medical in a deal potentially worth $150 million.
Read More
Precision ovarian cancer drug shows early promise
An experimental targeted treatment for ovarian cancer has shown promise in early clinical trials shrinking tumours in half of women with the disease.
Read More
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
- Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
